OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Dorff on the Investigation of PARP Inhibitors in mCRPC

January 10th 2023

Tanya Dorff, MD, discusses the investigation of PARP inhibitors in metastatic castration-resistant prostate cancer.

Dr. Kozuch on the Evaluation of ctDNA in the CIRCULATE-US Trial in Resected CRC

January 10th 2023

Peter Kozuch, MD, discusses the phase 2/3 CIRCULATE-US trial evaluating chemotherapy decisions for patients with resected colorectal cancer based on circulating tumor DNA status.

Dr. Ahluwalia on the Evaluation of SurVaxM With Temozolomide in Newly Diagnosed Glioblastoma

January 10th 2023

Manmeet Singh Ahluwalia, MD, discusses the evaluation of SurVaxM in combination with oral temozolomide in patients with newly diagnosed glioblastoma.

Dr. Force on the Efficacy of Trastuzumab Deruxtecan in the DESTINY-Breast02 Trial for HER2+ Breast Cancer

January 9th 2023

Jeremy Force, DO, discusses the efficacy of trastuzumab deruxtecan in pretreated patients with HER2-positive breast cancer on the phase 3 DESTINY-Breast02 trial.

Dr. Patel on the Sequencing of Immunotherapy and Targeted Therapy in BRAF-Mutant Melanoma

January 9th 2023

Sapna Patel, BA, MD, discusses the sequencing of immunotherapy and targeted therapy in BRAF-mutant melanoma.

Dr. Bartsch on the Real-World Evaluation of the ELEANOR Study in HR+/HER2-Overexpressed Breast Cancer

January 6th 2023

Rupert Bartsch, MD, discusses interim findings produced from the real-world use of neratinib in select patients with hormone receptor-positive, HER2-overexpressed breast cancer.

Dr. Niemann on Notable Findings from the GLOW Trial in CLL

January 6th 2023

Carsten Niemann, MD, PhD, discusses notable data on patient survival outcomes, as well as the impact of minimal residual disease in the peripheral blood from the phase 3 GLOW trial in patients with chronic lymphocytic leukemia.

Dr. Contreras on the Role of Neoadjuvant Pembrolizumab in Desmoplastic Melanoma

January 6th 2023

Carlo Contreras, MD, discusses the role of neoadjuvant pembrolizumab for the treatment of patients with desmoplastic melanoma.

Dr. Aragon-Ching on the Use of Maintenance Avelumab in Urothelial Carcinoma

January 6th 2023

Jeanny B. Aragon-Ching, MD, FACP, discusses the use of maintenance avelumab as the standard-of-care treatment for patients with locally advanced or metastatic urothelial carcinoma.

Dr. Lustberg on the Real-World Use of Ovarian Suppression in HR+/HER2+ Breast Cancer

January 5th 2023

Maryam Lustberg, MD, MPH, discusses the real-world use of ovarian suppression therapy in clinical practice for premenopausal patients with hormone receptor-positive, HER2-positive breast cancer.

Dr. Kruse on the Effect of Socioeconomic Disparities on Survival Outcomes in Breast Cancer

January 5th 2023

Megan Kruse, MD, discusses how socioeconomic disparities and access to health insurance can contribute to poorer overall survival (OS) outcomes in adolescent patients with invasive breast cancer.

Dr. Alvarnas on the Importance of Access to CAR T-cell Therapy in Cancer Care

January 5th 2023

Joseph Alvarnas, MD, discusses the importance of access to CAR T-cell therapy in cancer care.

Dr. Dadwal on the Investigation of Posoleucel Following Allogeneic HCT

January 5th 2023

Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.

Dr. Zakrzewski on Investigation of IT848 Nanotherapy in Hematologic Malignancies

January 5th 2023

Johannes Zakrzewski, MD, discusses the investigation of a nanoframework-based delivery system for IT848 in hematologic malignancies.

Dr. Verschraegen on the Need for Predictive Biomarkers for Immunotherapy in Melanoma

January 4th 2023

Claire F. Verschraegen, MD, discusses the need for predictive biomarkers for the use of immunotherapy in the treatment of melanoma.

Dr. Meisel on Effect of the HER2-Low Classification Breast Cancer

January 4th 2023

Jane L. Meisel, MD, discusses the effect of the HER2-low classification for patients with breast cancer.

Dr. Dorff on Second-line Immune Checkpoint Inhibitors in Metastatic RCC

January 4th 2023

Tanya Dorff, MD, discusses remaining questions regarding sequencing in metastatic renal cell carcinoma.

Dr. Sauter on Key Considerations for Posttransplant Pembrolizumab in T-cell NHL

January 4th 2023

Craig Sauter, MD, discusses important considerations regarding the use of pembrolizumab after autologous stem cell transplant in T-cell non-Hodgkin lymphoma.

Dr. Velcheti on the Evaluation of Anti-CTLA-4 Combination Regimens in Metastatic NSCLC

January 4th 2023

Vamsidhar Velcheti, MD, discusses the evaluation of immunotherapy combination regimens for patients with metastatic non–small cell lung cancer.

Dr. Abdallah on Interim Efficacy Data on HPN217 in R/R Multiple Myeloma

December 23rd 2022

Al-Ola A. Abdallah, MD, discusses interim results from an ongoing phase 1 trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma.